Physician
Vanjani, Rahul
Vanjani, Rahul was paid $119K by Medicaid between Mar 2018 and Oct 2022, across 11 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 49% of everything it billed.
33Billing provider infoVANJANI, RAHUL
PROVIDENCE, RI 02907
PROVIDENCE, RI 02907
33aNPI1134487135assigned 04/26/2012
33bProvider typeInternal Medicine Physician
28Total paid$119K
24GClaims2,520
24DCodes billed11
24AFirst – last monthMar 2018 – Oct 2022
Compared with peers
Next to other Internal Medicine Physician providers in Rhode Island
Rank by total paid#71 of 386
Median peer was paid$15K
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 312 | $17K | |
| 2019 | 487 | $21K | |
| 2020 | 648 | $39K | |
| 2021 | 737 | $28K | |
| 2022 | 336 | $14K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 49% | 1,344 | 1,064 | $59K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 9.4% | 83 | 62 | $11K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 8.8% | 210 | 198 | $11K |
| 36415 | Collection of venous blood by venipuncture | 6.5% | 393 | 318 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.9% | 85 | 85 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.8% | 63 | 49 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | 5.3% | 206 | 189 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.2% | 47 | 39 | $6K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.6% | 25 | 25 | $2K |
| 80061 | Lipid panel | 1.2% | 37 | 33 | $1K |
| 80053 | Comprehensive metabolic panel | 1.0% | 27 | 24 | $1K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.